MARKET NEWS

PhoreMost & POLARISqb Announce a Multi-Target Collaboration to Investigate Next-Generation Cancer Therapies
Akoya Biosciences & Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow With Industry-Leading Speed & Resolution
MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
Viridian Therapeutics Submits IND Application for VRDN-002 to the US FDA
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

Gattefossé provides functional excipient and innovative drug delivery solutions to beauty and healthcare industries worldwide. With service and distribution networks that span over 60 countries, Gattefossé prides itself on ensuring products that meet pharmaceutical industry needs from both regional and global perspectives. At Gattefossé, each excipient is designed to meet a unique set of formulation and functionality objectives while conforming to the highest safety, quality, and regulatory standards. Product applications include solubility and bioavailability enhancers; sustained/controlled release matrix formers; protective coatings or taste masking agents for actives; emulsifying bases for topical dosage forms; skin penetration and permeation enhancers; and carriers for suppository bases and vaginal pessaries. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines From AstraZeneca

Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines From AstraZeneca

Covis Pharma Group recently announced Covis Pharma GmbH has completed the acquisition of Eklira (aclidinium bromide), known as Tudorza in the US and marketed as Bretaris in some countries, and….

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

MannKind Corporation recently announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of….

Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….

Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications

Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications

Rain Therapeutics Inc. recently announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab…..

Cue Biopharma & LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

Cue Biopharma & LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

Cue Biopharma, Inc. and LG Chem Life Sciences recently announced a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT biologic, jointly developed to….

Curia Unveils Comprehensive mRNA Solution

Curia Unveils Comprehensive mRNA Solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 19 – Drug Delivery
January 26 – Bioavailability